Article Sidebar

PDF
Issue: No. 99 (2026)
Section: Article
DOI: 10.58490/ctjump.2026i99.4705
Date Published: 25/06/2026
Views 0
Downloads 0
How to Cite
La, D. H., Huynh, H. T., & Le, V. N. (2026). THE VALUE OF M2BPGi IN ASSESSING ADVANCED LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B. Cantho Journal of Medicine and Pharmacy, 99, 64-71. https://doi.org/10.58490/ctjump.2026i99.4705

THE VALUE OF M2BPGi IN ASSESSING ADVANCED LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B

Duc Huy La1,2, Hieu Tam Huynh1, , Van Nho Le3
1 Can Tho University of Medicine and Pharmacy
2 Tay Ninh General Hospital
3 Da Nang University of Medical Technology and Pharmacy

Main Article Content

Abstract

Background: Assessment of liver fibrosis in patients with chronic hepatitis B is essential for prognosis and treatment decision-making. In addition to liver stiffness measurement by FibroScan, serum Mac-2 binding protein glycosylation isomer (M2BPGi) has been proposed as a noninvasive biomarker reflecting the severity of liver fibrosis. Objectives: To investigate the correlation between serum M2BPGi levels and liver stiffness, and to evaluate the diagnostic performance of M2BPGi in detecting advanced fibrosis (F3–F4) in patients with chronic hepatitis B. Materials and methods: A cross-sectional descriptive study was conducted in 30 patients with chronic hepatitis B treated at Tay Ninh General Hospital from June 2025 to January 2026. Pearson correlation analysis was used to assess the association between FibroScan and M2BPGi. Receiver operating characteristic curve analysis was performed to determine the discriminative value of M2BPGi for advanced fibrosis. Data were analyzed using R version 4.5.0. Results: The mean age was 49.00 ± 13.29 years and 63.3% were male. Regarding laboratory characteristics, AST >40 U/L was observed in 18/30 patients (60.0%), ALT >40 U/L in 15/30 patients (50.0%), and high HBV DNA levels in 24/30 patients (80.0%). Mean M2BPGi level was 1.56 ± 1.39 C.O.I. Mean liver stiffness was 8.24 ± 3.44 kPa and 33.3% of patients had advanced fibrosis (F3–F4). Liver stiffness showed a strong positive correlation with M2BPGi (r = 0.76, p < 0.001). M2BPGi levels were significantly higher in the F3– F4 group compared with the F0–F2 group (p = 0.002). ROC analysis demonstrated excellent diagnostic performance of M2BPGi for advanced fibrosis with an AUC of 0.92 (95% CI 0.76–1.00). A cutoff value of 1.52 C.O.I yielded a sensitivity of 80.0% and a specificity of 95.0%. Conclusion: In patients with chronic hepatitis B, M2BPGi showed a strong correlation with liver stiffness and demonstrated high diagnostic accuracy for detecting advanced liver fibrosis. 

Keywords

Chronic hepatitis B, M2BPGi, FibroScan, liver fibrosis, diagnostic performance

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

References

1. Liu X, Zhang W, Ma B, Lv C, Sun M, Shang Q. The value of serum Mac-2 binding protein glycosylation isomer in the diagnosis of liver fibrosis: a systematic review and meta-analysis. Frontiers in physiology. 2024. 15, 1382293. doi:10.3389/fphys.2024.1382293.
2. Pham TND, Le DH, Dao DVB, Phan LTB, Pham TTT, Nguyen TB, et al. Establishing baseline framework for hepatitis B virus micro-elimination in Ho Chi Minh City, Vietnam - A community-based seroprevalence study. The Lancet regional health Western Pacific. 2023. 30, 100620. doi:10.1016/j.lanwpc.2022.100620.
3. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology (Baltimore, Md). 2018. 67(4), 1560-99. doi:10.1002/hep.29800.
4. Liver EAftSot. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. Journal of hepatology. 2021. 75(3), 659-89. doi:10.1016/j.jhep.2021.05.025.
5. Tamaki N, Kurosaki M, Loomba R, Izumi N. Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. Annals of laboratory medicine. 2021. 41(1), 16-24. doi:10.3343/alm.2021.41.1.16.
6. Tseng TC. Novel biomarkers for chronic hepatitis B management. Clinical liver disease. 2024. 23(1), e0155. doi:10.1097/cld.0000000000000155.
7. Bui HH, Nguyen ST, Phan ST, Nguyen KM, Nguyen CD. Evaluating M2BPGi as a Marker for Liver Fibrosis in Patients with Chronic Hepatitis B. Digestive diseases and sciences. 2023. 68(12), 4407-17. doi:10.1007/s10620-023-08143-5.
8. Bùi Thị Nhung, Huỳnh Hiếu Tâm. Khảo sát nồng độ M2BPGi huyết thanh và một số yếu tố liên quan ở bệnh nhân viêm gan siêu vi B mạn. Tạp chí Y học Việt Nam. 2026. 558(1). doi:10.51298/vmj.v558i1.16961.
9. Bộ Y tế. Hướng dẫn chẩn đoán, điều trị bệnh viêm gan vi rút B. Quyết định số: 3310/QĐ-BYT ngày 29 tháng 7 năm 2019.
10. Đỗ Văn Tá. Nghiên cứu mối liên quan giữa lâm sàng, cận lâm sàng với chỉ số fibroscan trong chẩn đoán xơ hóa gan ở bệnh nhân đến khám và điều trị tại Bệnh viện 199. Tạp chí Y học Việt Nam. 2024. 538(1), 227-31. https://doi.org/10.51298/vmj.v538i1.9360.
11. Mak L-Y, Wong DK-H, Seto W-K, Ning Q, Cheung K-S, Fung J, et al. Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. Hepatology International. 2019. 13(2), 148-56. doi:10.1007/s12072-019-09928-5.
12. Nguyễn Thị Vân Anh, Đào Việt Hằng. 29. Khảo sát nồng độ M2BPGi ở bệnh nhân viêm gan B mạn và xơ gan do viêm gan B. Tạp chí Nghiên cứu Y học. 2024. 181(8), 265-72. doi:10.52852/tcncyh.v181i8.2714.
13. Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clinical and translational gastroenterology. 2018. 9(6), 163. doi:10.1038/s41424-018-0020-9.